Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

被引:20
|
作者
Wulffelé, MG
Kooy, A
Lehert, P
Bets, D
Donker, AJM
Stehouwer, CDA
机构
[1] Bethesda Gen Hosp, Dept Internal Med, NL-7909 AA Hoogeveen, Netherlands
[2] FUCAM, Dept Stat, Fac Econ, Mons, Belgium
[3] E Merck Nederland BV, Clin Res & Dev, Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Amsterdam, Netherlands
[6] Univ Hosp Maastricht, Dept Med, Maastricht, Netherlands
关键词
blood pressure; metformin; randomized controlled trial; Type; 2; diabetes; 24-h ambulatory blood pressure monitoring;
D O I
10.1111/j.1464-5491.2005.01554.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We investigated in a double-blind study whether metformin reduces blood pressure (BP) in patients with Type 2 diabetes intensively treated with insulin. Methhods A total of 220 patients with Type 2 diabetes were asked to undergo 24-h ambulatory BP monitoring (24-h ABPM). One hundred and eighty-two gave informed consent. Eighty-nine were randomized to metformin and 93 to placebo. Thirty-five subjects dropped out (13 placebo, 22 metformin users); 147 patients underwent a second 24-h ABPM, 16 weeks after randomization. Results Systolic BP (SBP), diastolic BP (DBP), pulse BP (PP), mean BP (MP) and heart rate (HR) were measured as office BP measurements and as 24-h ABPM for 24-h, day and night. Office BP measurements did not differ significantly between the placebo- and metformin-treated groups for any BP measure, but showed a non-significant trend for SBP reduction with metformin use (mean baseline-adjusted difference, metformin minus placebo: -4.2 mmHg, 95% CI, -9.9 to +1.5; P = 0.15). The baseline-adjusted differences of the ambulatory measurements were -0.2 mmHg (95% CI, -2.9 to +2.6) for the 24-h SBP, and +1.1 mmHg (95% CI, -0.7 to +2.8) for the 24-h DBP. On the whole, BP differences between metformin- and placebo-treated groups were not statistically significant. The only significant difference was for night-time PP (baseline-adjusted difference: -2.2 mmHg; 95% CI, -4.2 to -0.2). These results were not different after adjustment for age and diabetes duration, or for (changes in) body mass index, glycated haemoglobin, insulin dose or plasma homocysteine. Conclusion Metformin does not significantly affect BP in patients with Type 2 diabetes intensively treated with insulin.
引用
收藏
页码:907 / 913
页数:7
相关论文
共 50 条
  • [41] Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients
    Alavudeen, Sirajudeen Shaik
    Khobrani, Moteb
    Dhanapal, C. K.
    Mir, Javid Iqbal
    Alshahrani, Sultan Mohammed
    Khan, Noohu Abdullah
    Alhossan, Abdulaziz
    SAUDI PHARMACEUTICAL JOURNAL, 2020, 28 (02) : 210 - 214
  • [42] Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France
    Vexiau, P.
    Mavros, P.
    Krishnarajah, G.
    Lyu, R.
    Yin, D.
    DIABETES OBESITY & METABOLISM, 2008, 10 : 16 - 24
  • [43] The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin
    Kashi, Zahra
    Masoumi, Parisa
    Mahrooz, Abdolkarim
    Hashemi-Soteh, Mohammad Bagher
    Bahar, Adele
    Alizadeh, Ahad
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (01) : 78 - 83
  • [44] Clinical outcomes in type 2 diabetes patients with chronic heart failure treated with metformin: a meta-analysis
    Huang, Wenxia
    Zhao, Rongchen
    ENDOCRINE, 2025, 87 (02) : 436 - 447
  • [45] Thymic emigration patterns in patients with type 2 diabetes treated with metformin
    Dworacki, Grzegorz
    Urazayev, Olzhas
    Bekmukhambetov, Yerbol
    Iskakova, Saule
    Frycz, Bartosz A.
    Jagodzinski, Pawel P.
    Dworacka, Marzena
    IMMUNOLOGY, 2015, 146 (03) : 456 - 469
  • [46] MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
    Wang, Na
    Zhang, Jin-Ping
    Xing, Xiao-Yan
    Yang, Zhao-Jun
    Zhang, Bo
    Wang, Xin
    Yang, Wen-Ying
    ARCHIVES OF MEDICAL SCIENCE, 2019, 15 (02) : 309 - 320
  • [47] The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials
    Zhang, Fan
    Xiang, Hao
    Fan, Yunzhou
    Ganchuluun, Tsend-ayush
    Kong, Wenhua
    Ouyang, Qian
    Sun, Jingwen
    Cao, Beibei
    Jiang, Hongbo
    Nie, Shaofa
    ENDOCRINE, 2013, 44 (03) : 648 - 658
  • [48] Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin
    Derosa, Giuseppe
    Fogari, Elena
    Cicero, Arrigo F. G.
    D'Angelo, Angela
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Salvadeo, Sibilla A. T.
    Gravina, Alessia
    Ferrari, Ilaria
    Fogari, Roberto
    HYPERTENSION RESEARCH, 2007, 30 (05) : 387 - 394
  • [49] Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin
    Giuseppe Derosa
    Elena Fogari
    Arrigo F G Cicero
    Angela D'angelo
    Leonardina Ciccarelli
    Mario N Piccinni
    Fabio Pricolo
    Sibilla A T Salvadeo
    Alessia Gravina
    Ilaria Ferrari
    Roberto Fogari
    Hypertension Research, 2007, 30 : 387 - 394
  • [50] Metformin for prevention of type 2 diabetes
    Hess, AM
    Sullivan, DL
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (7-8) : 1283 - 1285